Late at night, the whole network was scanned by a sudden blockbuster news from Xinhua News Agency.

Tu Youyou's team will announce major scientific breakthroughs on the 17th of this month, Xinhua reported. The Xinhua client released the news with a video and a poem. In the video, Tu Youyou, a Nobel laureate in physiology or medicine, said: "once the malaria parasite becomes resistant to artemisinin combination therapy, there will be no cure for malaria and mankind is bound to suffer havoc. Wang Jigang, a researcher at the Artemisinin Research Center of the Chinese Academy of traditional Chinese Medicine, said: "without artemisinin, millions of people would die every year. "

According to these descriptions, the major scientific breakthroughs to be released today may still be related to artemisinin!

In October 2015, Tu Youyou became the first native Chinese scientist to win the Nobel Science Prize for her discovery that artemisinin can effectively reduce the mortality rate of malaria patients. In the two years since then, Tu Youyou and her team launched a study on the possible mechanism of drug resistance to artemisinin and found that dihydroartemisinin has a unique effect on lupus erythematosus, according to media reports. The researchers also proved that artemisinin has some effects in the treatment of tumors, leukemia, rheumatoid arthritis, multiple sclerosis, allergic diseases and so on.

Market analysts believe that if there is a major breakthrough in artemisinin research, the traditional Chinese medicine plate represented by the concept of artemisinin will benefit from A-share listed companies. Among the listed companies, Shanghai Fosun Pharmaceutical's export volume of artemisia antimalarial drugs ranks first among Chinese enterprises, and Kunming Pharmaceutical Group, Zhejiang Pharmaceutical, Xinhecheng, China Resources Shuanghe and Baiyunshan may also benefit.

Tu Youyou brushed the screen late at night.

On the evening of June 16, a piece of news broke out by Xinhua News Agency, which hung up the appetite of the audience. Tu Youyou's team will announce major scientific breakthroughs on the 17th, according to Xinhua News Agency. The report does not give any description of major scientific breakthroughs, but is accompanied by a poem and a video.

In the video, Tu Youyou, a Nobel laureate in physiology or medicine, said that once the malaria parasite becomes resistant to artemisinin combination therapy, there will be no cure for malaria and mankind is bound to suffer havoc. In addition, Wang Jigang, a researcher at the Artemisinin Research Center of the Chinese Academy of traditional Chinese Medicine, said that without artemisinin, millions of people would die every year.

What kind of breakthrough will it be?

What kind of "popular style" will this be? The outside world doesn't know! A lot of concerned people are likely to have a sleepless night tonight. However, judging from previous media reports, the breakthrough may still be related to artemisinin.

In October 2015, Tu Youyou became the first native Chinese scientist to win the Nobel Science Prize for her discovery that artemisinin can effectively reduce the mortality rate of malaria patients. After that, she did not stop working on artemisinin.

Within two years of winning the Nobel Prize, Tu Youyou's team has officially published 15 scientific papers, including two important papers with an impact factor of more than 10, and three patents are being filed, the Xinhua Daily Telegraph reported. Research on the possible mechanism of drug resistance of artemisinin has also been launched. Tu Youyou's team also found that dihydroartemisinin has a unique effect on lupus erythematosus. According to existing clinical trials, artemisinin has an effective rate of more than 90% for discoid lupus erythematosus and more than 80% for systemic lupus erythematosus. The researchers also proved that artemisinin has some effects in the treatment of tumors, leukemia, rheumatoid arthritis, multiple sclerosis, allergic diseases and so on.

At that time, Tu Youyou said: "when we understand the antimalarial mechanism of artemisinin, we will be able to give full play to its efficacy and make better use of this drug, which is an important part of artemisinin research." Figuring out the "secret" of artemisinin is likely to be more than just its antimalarial effect. Tu Youyou told reporters at that time that she had seen artemisinin "hope in expanding indications."

There are signs that Tu Youyou's research breakthrough may still involve the potential of artemisinin.

These stocks may benefit from it.

If Tu Youyou's new breakthrough is still related to artemisinin, the artemisinin concept unit may benefit from it. In fact, these stocks reacted as early as when Tu Youyou won the Nobel Prize. According to the information summarized by Hexun at that time, the following companies are related to artemisinin:

$Shanghai Fosun Pharmaceutical (02196.HK) $Guilin Southern Medicine artesunate, a holding subsidiary, was officially certified by WHO-PQ in 2010. Three of the five prescriptions recommended by WHO contain artesunate. The innovative drug Artesun (artesunate for injection) is the first in the world and has become the first choice for the treatment of severe malaria strongly recommended by WHO. In 2014, the sales of Fosun artesunate drugs exceeded 200 million yuan.

$Kunming Pharmaceutical Group (600422.SH) $Kunyao is a supplier of Novartis Artemisia methyl ether raw materials, and has the production approval of artemether injection. On September 29, 2015, Kunming medicine completed its acquisition of Huafang Ketai and obtained artemisinin products such as dihydroartemisinin piperaquine tablets. At present, Kunming medicine artemether injection and dihydroartemisinin piperaquine tablets (Ketaifu) are applying for WHO-PQ certification. At the end of 2018, Kunming Pharmaceutical Group and the Bill and Melinda Gates Foundation (hereinafter referred to as "the Foundation") signed the "Kunming Pharmaceutical Group Kotaifu (dihydroartemisinin phosphate piperaquine phosphate) WHO pre-certification cooperation" agreement.

Zhejiang Medicine (600216.SH) $Supplier of benflumetol, a component of Novartis Coartem (artemether + benflumetol), with the approval of artemether raw materials.

$Xinhe Cheng (002001.SZ) $With artesunate preparation and raw materials, dihydroartemisinin preparation approval.

$China Resources Crane (600062.SH) $With approval of dihydroartemisinin preparation.

$Baiyun Mountain (00874.HK) $There is artemisinin approval.